Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00879333
Registration number
NCT00879333
Ethics application status
Date submitted
8/04/2009
Date registered
10/04/2009
Date last updated
3/11/2015
Titles & IDs
Public title
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
Query!
Scientific title
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Query!
Secondary ID [1]
0
0
2008-006544-20
Query!
Secondary ID [2]
0
0
CRAD001R2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GRANITE-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Gastric Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Everolimus
Treatment: Drugs - Everolimus placebo
Treatment: Drugs - Best Supportive Care (BSC)
Experimental: Everolimus + BSC - All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
Placebo Comparator: Placebo + BSC - All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
Treatment: Drugs: Everolimus
Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Treatment: Drugs: Everolimus placebo
Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Treatment: Drugs: Best Supportive Care (BSC)
Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
The primary objective of this study was to compare OS between everolimus + best supportive care (BSC) and placebo + BSC. OS, was defined as the time from date of randomization to the date of death due to any cause. If at the analysis cut-off date a patient was not known to have died, survival was censored at the date of the last contact. OS was analyzed using the Kaplan Meier estimates method.
Query!
Timepoint [1]
0
0
2.5 years
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
Progression free survival was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, where progression was based on Investigator assessment of baseline and post-baseline scans according to RECIST. Progression free survival was censored if no PFS event was observed before the first to occur out of (i) the cut-off date, or (ii) the date when a further anticancer therapy was started. The censoring date was the date of the last adequate tumor assessment before either of these two events occurred. If a PFS event was observed after two or more missing or non-evaluable tumor assessments, then the date of progression was censored at the date of the last adequate tumor assessment; for a PFS event observed after a single missing or non-evaluable tumor assessment, the actual date of disease progression was used. Anslsis was done using Kaplan-Meier estimates method.
Query!
Timepoint [1]
0
0
2.5 years
Query!
Secondary outcome [2]
0
0
Patient Reported Outcome (PRO): Time to Definitive Deterioration of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Scores
Query!
Assessment method [2]
0
0
The EORTC QLQ-C30 global health status/quality of life sub-scale (QL) was pre-specified as the primary domain of interest, followed by physical functioning (PF), social functioning (SF) and emotional functioning (EF).The EORTC QLQ-C30 questionnaire, along with a module specific for gastric cancer patients (EORTC QLQ-STO22), was used to evaluate PRO. The QLQ-C30 has five function scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and a global health status/quality of life scale. In addition, there are questions that assess specific symptoms. The QLQ-STO22 consists of 22 questions that make up five multi-item scales (dysphagia, pain, reflux, eating and anxiety) and four single-item scales (dry mouth, tasting, body image and hair loss).
Query!
Timepoint [2]
0
0
2.5 years
Query!
Secondary outcome [3]
0
0
Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
Query!
Assessment method [3]
0
0
The ECOG PS scale was used to classify patients according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). An analysis of the time to definitive deterioration of the ECOG PS by one category of the score from baseline was performed. Definitive deterioration was defined as a definitive increase by one category from baseline in ECOG PS, with no later improvements observed during the course of the study. A single measure reporting an increase in ECOG PS is sufficient to consider it as a definitive worsening only if it was the last one available for the patient. Kaplan-Meier method was used to estimate the distribution function of time to definitive worsening.
Query!
Timepoint [3]
0
0
2.5 years
Query!
Secondary outcome [4]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [4]
0
0
ORR was defined as the proportion of patients with measurable disease in whom best overall response (OR) was either complete response (CR) or partial response (PR) according to RECIST criteria.
Query!
Timepoint [4]
0
0
2.5 years
Query!
Secondary outcome [5]
0
0
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax at Week 5
Query!
Assessment method [5]
0
0
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
Query!
Timepoint [5]
0
0
Week 5
Query!
Secondary outcome [6]
0
0
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5
Query!
Assessment method [6]
0
0
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
Query!
Timepoint [6]
0
0
Week 5
Query!
Eligibility
Key inclusion criteria
- Male or female patients > 18 years old
- Histologically or cytologically confirmed and documented gastric adenocarcinoma
- Documented progression after 1 or 2 prior chemotherapy treatments for advanced disease
- ECOG Performance Status of < 2
- Lab parameters within specifically defined intervals
- Able to provide written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients who have received > 2 prior systemic therapies for advanced disease
- Administration of another anticancer therapy within 3 weeks prior to randomization
- Chronic treatment with steroids or another immunosuppressive agent
- Major surgery within 2 weeks prior to randomization
- Patients with CNS metastases
- Any other severe and/or uncontrolled medical condition
Other protocol-defined inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
656
Query!
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Canberra
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Herston
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Kurralta Park
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - North Adelaide
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Box Hill
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - Clayton
Query!
Recruitment hospital [7]
0
0
Novartis Investigative Site - Footscray
Query!
Recruitment hospital [8]
0
0
Novartis Investigative Site - Heidelberg
Query!
Recruitment hospital [9]
0
0
Novartis Investigative Site - Prahran
Query!
Recruitment postcode(s) [1]
0
0
2605 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [4]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [7]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
3181 - Prahran
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Washington
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Viedma
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Buenos Aires
Query!
Country [9]
0
0
Argentina
Query!
State/province [9]
0
0
Cordoba
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Charleroi
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Gent
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Leuven
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Liege
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
British Columbia
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Quebec
Query!
Country [17]
0
0
China
Query!
State/province [17]
0
0
Guangdong
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Hebei
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Heilongjiang
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Jiangsu
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Liaoning
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Sichuan
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Zhejiang
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Beijing
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Guangzhou
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Shanghai
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Avignon Cedex
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Clermont Ferrand cedex 1
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Clichy
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Dijon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Lyon Cedex 08
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Marseille cedex 05
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Montpellier Cedex 5
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Nice Cedex 2
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Paris
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Pessac Cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Poitiers
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Reims
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rennes Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Toulouse Cedex 4
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Villejuif Cedex
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Baden-Württemberg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Bielefeld
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Frankfurt
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Mainz
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
München
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Offenburg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Trier
Query!
Country [50]
0
0
Hong Kong
Query!
State/province [50]
0
0
Hong Kong SAR
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petach Tikva
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Ramat Gan
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Rehovot
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
FI
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
MI
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
MO
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
PN
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Frattamaggiore
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Aichi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Chiba
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Ehime
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Fukuoka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Hokkaido
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Kanagawa
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Miyagi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Osaka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Saitama
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Tochigi
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Tokyo
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Jeollabuk-do
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Korea
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Taegu
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Distrito Federal
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Guanajuato
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Amsterdam
Query!
Country [78]
0
0
New Zealand
Query!
State/province [78]
0
0
Auckland
Query!
Country [79]
0
0
Peru
Query!
State/province [79]
0
0
Lima
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Moscow
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
St. Petersburg
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Catalunya
Query!
Country [83]
0
0
Taiwan
Query!
State/province [83]
0
0
Taoyuan/ Taiwan ROC
Query!
Country [84]
0
0
Taiwan
Query!
State/province [84]
0
0
Liouying Township
Query!
Country [85]
0
0
Taiwan
Query!
State/province [85]
0
0
Niaosong Township
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Taipei
Query!
Country [87]
0
0
Thailand
Query!
State/province [87]
0
0
Bangkok
Query!
Country [88]
0
0
Thailand
Query!
State/province [88]
0
0
Songkla
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Middlesex
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Surrey
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
East Yorkshire
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
London
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Manchester
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients
with advanced gastric cancer which has progressed after one or two lines of prior
chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00879333
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00879333
Download to PDF